Latest Oncothyreon Inc. Stories
COMPANY TO RESTATE EITHER DISCLOSURE OR ACCOUNTING TREATMENT SEATTLE, WA, March 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will restate its 2008 financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2009 to correct a revenue recognition error in accounting for a license agreement with Merck KGaA signed in...
SEATTLE, WA, March 8 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that Gamehost Income Fund ("Gamehost") has determined that certain proposed changes to the Income Tax Act (Canada) announced on March 4, 2010 by the Canadian Federal Minister of Finance will adversely affect the benefit to Gamehost of the arrangement between it and Oncothyreon, previously announced on February 18, 2010, pursuant to which Oncothyreon was to sell its interests in Oncothyreon Canada...
SEATTLE, Feb. 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it has entered into an arrangement agreement (the "Arrangement") pursuant to which it will sell its interests in Oncothyreon Canada Inc., an indirect wholly owned subsidiary, and 0811769 B.C. ULC, an indirect wholly owned subsidiary and the parent corporation of Oncothyreon Canada Inc., for approximately Cdn $8.425 million to Gamehost Income Fund ("Gamehost"). Prior to the sale, Oncothyreon Canada...
SEATTLE, Nov. 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior...
SEATTLE, Nov. 11 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the three and nine months ended September 30, 2009 and provided a product pipeline update. Management will hold a conference call today at 4:30 p.m. ET, 1:30 p.m. PT (see below for details). Oncothyreon reported a loss from operations of $2.8 million for the three months ended September 30, 2009, compared with a loss from operations of $3.6 million for the comparable period in...
SEATTLE, Nov. 2 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its third quarter 2009 financial results on Wednesday, November 11, 2009 after market close. Following the release, Oncothyreon's management expects to discuss these financial results and give a general business update in a conference call at 4:30 p.m. EST....
SEATTLE, Oct. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) today announced the appointment of Douglas E. Williams, Ph.D., Chief Executive Officer of ZymoGenetics, Inc. (Nasdaq: ZGEN), to its board of directors. "We are pleased to welcome Doug to our board of directors and look forward to the contributions he will make to Oncothyreon. His extensive experience in drug development, research and operations will be invaluable," said Robert L. Kirkman, M.D., President and...
SEATTLE, WA, Sept. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman Renshaw 11th Annual Healthcare Conference taking place Sept. 9-11, 2009 in New York. Dr. Kirkman will present at 2 p.m. Eastern Time on Thursday, Sept. 10. A live and archived webcast of the presentation will be accessible at http://www.wsw.com/webcast/rrshq15/onty or by visiting the...
SEATTLE, Aug. 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008. Oncothyreon recorded a non-cash charge of $2.5 million in the three months ended June 30, 2009 for the change in the fair value of warrants issued in connection with its...
SEATTLE, Aug. 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for gross proceeds of approximately $15.0 million on August 7, 2009. Oncothyreon sold the shares and warrants for $6.5775 per unit (each unit consisting of one share and a warrant to purchase 0.30 shares of common...
